Murat ÇELİK, Barış BUĞAN, Turgay ÇELİK, Halil YAMAN, Atila İYİSOY

Comparative effects of levosimendan and dobutamine infusion on p wave dispersion in patients with acute decompensated heart failure

We aimed to evaluate the comparative effects of levosimendan and dobutamine on P-wave dispersion (PWD) in the patients with acute decompensated heart failure (ADHF). Materials and methods: The study population consisted of 40 patients (mean age = 68 years, 23 men, NYHA class III-IV) presented with ADHF. Patients were randomized to intravenous levosimendan (n = 20) or dobutamine (n = 20) groups. The P-wave duration measurements were calculated in 12-lead surface ECG simultaneously and recorded before and after treatment. Manual measurements of P-wave duration were performed with digital calipers on a high resolution computer screen by two cardiologists not aware of the patients' clinical data. Results: There were no significant changes in P max in the dobutamine group whereas a significant decrease was observed in the levosimendan group after the infusion. The levosimendan infusion significantly reduced PWD (from 40 msec to 30 msec, P < 0.001) but the dobutamine infusion has no effect on PWD. In hospital new onset atrial fibrillation (AF) frequency was similar among two groups. Conclusion: Levosimendan infusion significantly reduces PWD compared to dobutamine infusion in our study population. This finding may be related to hemodynamic improvements provided by levosimendan.

Anahtar Kelimeler:

Key words: Acute decompensated heart failure, dobutamine, levosimendan, P-wave dispersion

Comparative effects of levosimendan and dobutamine infusion on p wave dispersion in patients with acute decompensated heart failure

Keywords:

Key words: Acute decompensated heart failure, dobutamine, levosimendan, P-wave dispersion,

PDF

___

Felker GM, O'Connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J 2001; 142: 393-401. 2. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS et al.. Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287: 1541-7.
Bayram M, De Luca L, Massie MB, Gheorghiade M.
Reassessment of dobutamine, dopamine, and milrinone in the
management of acute heart failure syndromes. Am J Cardiol
; 96: 47G-58G. 4.
Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Lindén IB.
Cardiac troponin C as a target protein for a novel calcium
Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K et al. Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360: 196- 202.
Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325: 1468–75.
Nony P, Boissel JP, Lievre M, Leizorovicz A, Haugh MC, Fareh S et al. Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A metaanalysis. Eur J Clin Pharmacol 1994; 46: 191–6.
Singh BN, Lilleberg J, Sandell E-P, Ylönen V, Lehtonen L, Toivonen L. Effects of levosimendan on cardiac arrhythmias: electrophysiologic and ambulatory electrocardiographic findings in Phase II and III clinical studies in cardiac failure. Am J Cardiol 1999; 24 Suppl I: 16(I)–20(I).
Lilleberg J, Ylönen V, Lehtonen L, Toivonen L. The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies. Scand Cardiovasc J 2004; 38: 80-4.
Dilaveris P, Batchvarov V, Gialafos J, Malik M. Comparison of different methods for manual P-wave duration measurement in 12-lead electrocardiograms. Pacing Clin Electrophysiol 1999; 22: 1532-8.
Edes I, Kiss E, Kitada Y, Powers FM, Papp JG, Kranias EG et al. Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 1995; 77: 107-13.
Sorsa T, Pollesello P, Solaro RJ. The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin C. Mol Cell Biochem 2004; 266: 87-107.
Haikala H. Non-clinical studies on arrythmogenity of levosimendan. Research Report: Orion Pharma; 2003 November 11 Report No: NDO090017.
Moiseyev VS, Põder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB et al. RUSSLAN Study Investigators. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002; 23: 1422-32.
Binkley PF, Nunziata E, Hatton PS, Leier CV. The positive inotropic agent levosimendan mediates increased cardiac output without progression of sympathovagal imbalance in patients with heart failure. Circulation 2000; 102 (Suppl II): 720–1.
Toivonen L, Viitasalo M, Sundberg S, Akkila J, Lehtonen L. Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function. J Cardiovasc Pharmacol 2000; 35: 664-9.
Packer M. REVIVE II: Multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure. Program and abstracts from the American Heart Association Scientific Sessions 2005; November 13-16, 2005; Dallas, Texas. Late Breaking Clinical Trials II.
Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ et al. SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007; 297: 1883-91.
Dilaveris PE, Gialafos JE. P-wave dispersion: A novel predictor of paroxysmal atrial fibrillation. Ann Noninvasive Electrocardiol 2001; 6: 159–65.
Parissis JT, Panou F, Farmakis D, Adamopoulos S, Filippatos G, Paraskevaidis I et al. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 2005; 96: 423-6.
Janssen PM, Datz N, Zeitz O, Hasenfuss G. Levosimendan improves diastolic and systolic function in failing human myocardium. Eur J Pharmacol 2000; 404: 191-9. Tachibana H, Cheng HJ, Ukai T, Igawa A, Zhang ZS, Little WC et al. Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure. Am J Physiol Heart Circ Physiol 2005; 288: H914-22.